<DOC>
	<DOCNO>NCT00071331</DOCNO>
	<brief_summary>The purpose study compare effectiveness tolvaptan placebo adult worsen congestive heart failure ( CHF ) .</brief_summary>
	<brief_title>EVEREST : Efficacy Vasopressin Antagonism hEart failuRE : Outcome Study With Tolvaptan</brief_title>
	<detailed_description>Study Design : Multicenter , randomize , double-blind , placebo-controlled</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Age great equal 18 year . Current hospitalization chronic congestive heart failure admission 48 hour prior randomization . Chronic heart failure define require treatment minimum 30 day prior hospitalization . The subject must sign extracellular volume expansion , define two follow : ) jugular venous distention ; b ) pitting edema ( &gt; 1+ ) ; c ) dyspnea . NYHA Class III IV time hospitalization . Left Ventricular Ejection Fraction &lt; = 40 % within one year . Exclusion Criteria Women adhere reproductive precaution outline Informed Consent form . Positive urine pregnancy test . Inability provide write informed consent . Cardiac surgery within 60 day potential study enrollment , exclude percutaneous coronary intervention . Planned revascularization procedure , electrophysiologic ( EP ) device implantation , cardiac mechanical support implantation , cardiac transplantation , cardiac surgery within 30 day follow study enrollment . Subjects cardiac mechanical support . History biventricular pacer placement within last 60 day . Comorbid condition expect survival less six month . Subjects acute ST segment elevation myocardial infarction time hospitalization . History sustain ventricular tachycardia ventricular fibrillation within 30 day , unless presence automatic implantable cardioverter defibrillator . History cerebrovascular accident within last 30 day . Hemodynamically significant uncorrected primary cardiac valvular disease . Hypertrophic cardiomyopathy ( obstructive nonobstructive ) . CHF due uncorrected thyroid disease , active myocarditis know amyloid cardiomyopathy . Subjects progressive episodic neurological disease multiple sclerosis history multiple stroke . History primary significant liver disease acute hepatic failure , define investigator . History poorly control diabetes mellitus . Morbid obesity , define &gt; 159 kg ( 350 lb ) BMI &gt; 40 . Supine systolic arterial blood pressure &lt; 90 mmHg . Serum creatinine &gt; 3.5 mg/dL &gt; 309.4 mmol/L . Serum potassium &gt; 5.5 mEq/L &gt; 5.5 mmol/L . Hemoglobin &lt; 9 g/dL &lt; 90 g/L . History hypersensitivity and/or idiosyncratic reaction benzazepine derivative ( benazapril ) . History drug medication abuse within past year , current alcohol abuse . Inability take oral medication . Participation another clinical drug device trial within past 30 day . Previous participation tolvaptan clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>chronic heart failure</keyword>
	<keyword>heart failure</keyword>
</DOC>